# Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

> **NCT04720664** · PHASE2 · TERMINATED · sponsor: **Georgetown University** · enrollment: 11 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer
- Hormone Receptor Positive Breast Carcinoma

## Interventions

- **DRUG:** SM-88

## Key facts

- **NCT ID:** NCT04720664
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-22
- **Primary completion:** 2023-02-10
- **Final completion:** 2023-02-10
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2023-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04720664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04720664, "Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04720664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*